The SBI Healthcare Opportunities Fund outperformed sector peers with an 8.9% return over the past month. While it leads short-to-medium-term performance rankings, investors should note that sector fund leadership can shift significantly over longer periods, with different schemes leading the three-year category.
What Happened
The SBI Healthcare Opportunities Fund has emerged as the leading performer among major pharmaceutical and healthcare mutual funds for the one-month period ending July 2, 2026. The fund delivered a return of 8.9%, outshining other schemes in the category such as the DSP Healthcare Fund, which reported a 7.6% return, and the Mirae Asset Healthcare Fund at 6.1%. This performance analysis focused on funds with an Assets Under Management (AUM) size of at least ₹1,500 crore.
Performance Relative to Benchmarks
A key driver of this performance has been the fund’s ability to generate returns significantly higher than its designated benchmark. Data indicates that while the benchmark for the fund remained flat at 0.0% for the one-month period, the fund achieved a gain of 8.9%. This trend of outperformance is also evident over a one-year horizon, where the fund recorded a 14.9% return compared to the 4.4% return of its benchmark, marking a lead of 10.5 percentage points.
Examining Different Timeframes
While the fund shows strong momentum in the short and medium term—including leading the pack with a 16.9% return over the last six months—it does not hold the top spot in every category. When looking at a three-year timeframe, the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund currently leads with a return of 25.4%. This variation illustrates that sector-specific funds can experience performance shifts based on the specific stocks held within their portfolios and market conditions during different economic cycles.
The Size of Sector Players
In terms of total assets managed, the Nippon India Pharma Fund holds the largest corpus among the top five schemes in this sector, managing ₹8,635.7 crore. For comparison, the SBI Healthcare Opportunities Fund manages a corpus of ₹4,566.0 crore. A larger AUM can sometimes influence a fund manager's flexibility, as deploying capital into smaller, high-growth pharmaceutical stocks becomes more difficult as the total fund size increases.
What Investors Should Track
Investors considering sector-specific mutual funds often look at these performance tables, but it is essential to consider the inherent volatility of the pharmaceutical and healthcare industry. Factors such as changes in drug pricing regulations, clinical trial outcomes for major pharmaceutical companies, and export demand from key international markets like the US can impact stock performance, which in turn drives the returns of these funds. Before making decisions, investors may look at the fund's top holdings, expense ratio, and whether their existing portfolio is already overexposed to the healthcare sector.